Loss of histochernical identity in mast cells lacking carboxypeptidase A by Feyerabend, Thorsten B. et al.
MOLECULAR AND CELLULAR BIOLOGY, July 2005, p. 6199–6210 Vol. 25, No. 14
0270-7306/05/$08.000 doi:10.1128/MCB.25.14.6199–6210.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Loss of Histochemical Identity in Mast Cells Lacking
Carboxypeptidase A
Thorsten B. Feyerabend,1 Heinz Hausser,2 Annette Tietz,1 Carmen Blum,1 Lars Hellman,3
Anita H. Straus,4 He´lio K. Takahashi,4 Ellen S. Morgan,5 Ann M. Dvorak,5
Hans Jo¨rg Fehling,1 and Hans-Reimer Rodewald1*
Department of Immunology1 and Department of Orthopedics,2 University of Ulm, D-89070 Ulm,
Germany; Department of Cell and Molecular Biology, Biomedical Center, Uppsala University,
S-751 24 Uppsala, Sweden3; Department of Biochemistry, Escola Paulista de Medicina,
Universidade Federal de Sa˜o Paulo, Sa˜o Paulo 04023-900, Brazil4; and
Department of Pathology, Beth Israel Deaconess Medical Center,
330 Brookline Avenue, Boston, Massachusetts 022155
Received 7 December 2004/Returned for modification 17 March 2005/Accepted 21 April 2005
Mast cell carboxypeptidase A (Mc-cpa) is a highly conserved secretory granule protease. The onset of
expression in mast cell progenitors and lineage specificity suggest an important role for Mc-cpa in mast cells.
To address the function of Mc-cpa, we generated Mc-cpa-null mice. Mc-cpa/ mast cells lacked carboxypep-
tidase activity, revealing that Mc-cpa is a nonredundant enzyme. While Mc-cpa/ peritoneal mast cells were
ultrastructurally normal and synthesized normal amounts of heparin, they displayed striking histochemical
and biochemical hallmarks of immature mast cells. Wild-type peritoneal mast cells had a mature phenotype
characterized by differential histochemical staining with proteoglycan-reactive dyes (cells do not stain with
alcian blue but stain with safranin and with berberine) and a high side scatter to forward scatter ratio by flow
cytometry and were detergent resistant. In contrast, Mc-cpa/ peritoneal mast cells, like immature bone
marrow-derived cultured mast cells, stained with alcian blue normally or weakly and either did not stain with
safranin and berberine or stained weakly, had a low side scatter to forward scatter ratio, and were detergent
sensitive. This phenotype was partially ameliorated with age. Thus, histochemistry and flow cytometry, com-
monly used to measure mast cell maturation, deviated from morphology in Mc-cpa/ mice. The Mc-cpa/
mast cell phenotype was not associated with defects in degranulation in vitro or passive cutaneous anaphylaxis
in vivo. Collectively, Mc-cpa plays a crucial role for the generation of phenotypically mature mast cells.
Mast cells are key mediators of host defense and inflamma-
tory reactions by releasing upon activation a range of inflam-
matory substances which include proteases, histamine, hepa-
rin, cytokines, chemokines, and lipid mediators. Once in the
extracellular space, the mediators can regulate, for instance,
local blood flow, vascular permeability, smooth muscle con-
traction, and connective tissue remodeling (reviewed in refer-
ences 6, 13, 22, and 48).
Mast cell proteases represent major protein components of
secretory granules, but the role of each individual protease in
mast cells remains poorly understood. The proteases are clas-
sified into a carboxypeptidase, chymases, and tryptases (re-
viewed in reference 16). Mast cells differ in their protease
expression pattern depending on the tissue location where they
reside (7, 33, 42) (reviewed in references 13 and 21). According
to this classification, connective tissue mast cells (CTMC) are
located primarily in the skin and at serosal sites, such as the
peritoneal cavity. CTMC express, in addition to mast cell car-
boxypeptidase A (Mc-cpa), mouse mast cell protease 2 (Mcp-
2), Mcp-4, Mcp-5, Mcp-6, and Mcp-7. CTMC are present con-
stitutively, i.e., in the absence of an immune response involving
mast cells (reviewed in reference 40). Mucosal mast cells
(MMC) express a different protease spectrum, primarily Mcp-1
and Mcp-2, and their cell numbers increase upon inflammation
at mucosal sites (reviewed in reference 19).
CTMC and MMC express different proteoglycans (reviewed
in references 28 and 41). CTMC synthesize and store in their
granules heparin, a highly sulfated glycosaminoglycan which
can be specifically detected by berberine sulfate staining (8). In
contrast, MMC synthesize predominantly chondroitin sulfate,
but not heparin. Alcian blue (AB) and safranin (S) are com-
monly used histochemical dyes which stain CTMC and MMC
differentially. CTMC do not stain with alcian blue but stain
with safranin (AB S), and MMC show the reverse staining
pattern (AB S). This differential staining reactivity probably
reflects the balance of heparin and chondroitin sulfate synthe-
sized by CTMC and MMC, respectively (7, 14, 45).
The onset of protease expression in mast cell ontogeny dif-
fers between various mast cell proteases. Mc-cpa, a mast cell-
specific gene (32), is expressed in the earliest known mast
cell-committed progenitors identified in fetal blood as cells
expressing high levels of c-Kit and low levels of Thy-1 and
lacking FcεRI expression (34). Mc-cpa is also, albeit weakly,
expressed in immature bone marrow (BM)-derived mast cell
cultures (BMMC) (5, 14, 36). In mature mast cells, Mc-cpa is
abundantly expressed in CTMC but only weakly in MMC (14,
36). The genes encoding Mc-cpa are highly conserved in mice
(36) and humans (31), suggesting a common but not yet known
role in both species. Mc-cpa is an exopeptidase which prefer-
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entially cleaves C-terminal aliphatic amino acids. Natural sub-
strates of Mc-cpa are unknown.
Some proteases form complexes within the mast cell prior to
degranulation. Mc-cpa, a major protein component in secre-
tory granules, is released complexed to proteoglycans upon
mast cell degranulation (36). Both Mc-cpa and Mcp-5 are
bound to heparin. Mc-cpa appears to depend on Mcp-5 ex-
pression because Mcp-5-deficient mast cells lack Mc-cpa pro-
tein, but not mRNA expression (16). Heparin itself is an es-
sential component in these complexes as shown in mast cells
lacking sulfated heparin (10, 17). During heparin synthesis,
most of the N-acetylglucosamine residues are modified by N
deacetylation and N sulfation. These modification steps are
catalyzed by glucosaminyl N-deacetylase/N-sulfotransferase 2
(Ndst-2). Ndst-2-deficient mast cells lack Mcp-4, Mcp-5,
Mcp-6, and mature Mc-cpa proteins (10, 15, 17). These find-
ings strongly implicate heparin as a central assembly or storage
site of protease-heparin complexes (reviewed in reference 50).
As a consequence, Ndst-2/ mast cells are poorly granulated
(17), and their secretory granules are ultrastructurally enlarged
and appear empty (10).
We report here that Mc-cpa/ mast cells lack Mc-cpa pro-
tein and, concomitantly, Mcp-5 but do contain Mcp-4, and
Mcp-6 proteins. On the basis of metabolic labeling with
[35S]sulfate and on HNO2 degradation, heparin synthesis is
unaffected by the loss of Mc-cpa. Peritoneal mast cells (PMC)
develop in normal numbers in Mc-cpa/ mice, but these mast
cells have an immature phenotype akin to that of BMMC as
assessed by light microscopic histochemistry. Our data imply
an important constitutive, activation-independent role for a
mast cell protease in normal mast cell development.
MATERIALS AND METHODS
Targeting of the Mc-cpa locus in ES cells. Homologous sequences for the
targeting vector were amplified by PCR from a 129/SvJ bacterial artificial chro-
mosome (Incyte Genomics). The targeting vector consisted, from 5 to 3, of the
5 arm (nucleotides 818 to 8 of the Mc-cpa gene [51]), an Egfp minigene (9),
a loxP-flanked neomycin resistance gene (12), the 3 arm (nucleotides 18 to
8024 of the Mc-cpa gene) (30, 32), and the herpes simplex virus thymidine
kinase gene for negative selection. Embryonic stem (ES) cells (E14.1; 129/0la)
were electroporated with the NotI-linearized targeting vector. Clones that had
undergone homologous recombination were identified by PCR using a Mc-cpa 5
oligonucleotide (5-CTTTAATTCCAGCACTTGGATTTCG-3) and an Egfp
3-oligonucleotide (5-CCGGACACGCTGAACTTGTGGC-3). Homologous
recombination was confirmed by Southern blotting. DNA was digested with
EcoRV or with SphI and XhoI. Blots were hybridized with a radiolabeled 1.2-kb
5 external probe (see Fig. 1A). The neo gene was excised by transient transfec-
tion with a Cre recombinase expression vector. The loss of neo was verified by
G418 sensitivity and by sequencing across the remaining loxP site. ES cell clones
were injected into BDF1 blastocysts, and chimeric male founder mice were
crossed to C57BL/6 (B6) females.
Mice. Mice were maintained under specific-pathogen-free conditions. Mc-
cpa/, Mc-cpa/, and Mc-cpa/ mice were littermates from intercrosses of
129  B6 F1 mice or lines of Mc-cpa/ and Mc-cpa/ mice established from
the fourth backcross to B6 mice. Mice were genotyped by PCR using oligonu-
cleotides annealing upstream of the 5 arm (5-CTGACAGTGGCCAACTGTA
AG-3) and within the 3 arm (5-CTCAATGCTTTGGGTCAAGTTC-3),
yielding 2.2-kb (Mc-cpa) and 3.7-kb (Mc-cpa) fragments (see Fig. 1C).
Mast cell cultures. BMMC were established by culture of BM cells at 5  105
cells per ml in Iscove’s modified Dulbecco’s medium (Gibco) supplemented with
1% interleukin 3 (IL-3) supernatant from an Il-3 gene-transfected cell line (18),
and 50 ng/ml recombinant stem cell factor (R&D Systems). After 4 weeks, the
vast majority of BMMC expressed c-Kit, FcεRI, and the mast cell marker T1
(25).
Flow cytometry. Antibodies used were allophycocyanin-labeled anti-c-Kit
(2B8; Pharmingen), immunoglobulin E (IgE) (SPE-7; Sigma) followed by fluo-
rescein isothiocyanate (FITC)-labeled anti-IgE (R35-72; Pharmingen), or FITC-
labeled anti-T1 (DJ8; Morwell Diagnostics). Fc receptors were blocked with 0.5
mg/ml mouse IgG (Dianova) prior to staining. Cells were stained, analyzed, and
sorted as described previously (47) using FACSCalibur and FACSAria instru-
ments (Becton Dickinson). Data are displayed as dot plots using CellQuest or
FACSDiva software.
Histochemistry, immunofluorescence, and determination of cell numbers.
Mast cells were cytospun (Cytospin3; Shandon) onto glass slides at 700 rpm for
5 min and stained with toluidine blue or alcian blue and safranin or with ber-
berine (1). For berberine staining of tissue mast cells, 5-m paraffin sections of
ears fixed in Carnoy’s fluid (ethanol:chloroform:acetic acid, 6:3:1) overnight and
then in 100% ethanol for 8 h were dewaxed by heating the glass slides to 80°C.
Remaining paraffin was removed by successive washes with xylol and ethanol.
Further staining procedure was as for berberine staining on cytospins. For tolu-
idine staining of ear sections, paraffin ear sections fixed in Carnoy’s fluid and
dewaxed were subjected to a descending series of ethanol solutions (96%, 80%,
70%, and 50% ethanol, and water), and subsequently stained for 10 min in 0.3%
aqueous toluidine solution. After a brief wash with water, specimens were de-
hydrated with 96% and 99% ethanol. After a final incubation in xylol, slides were
mounted with Entellan (Merck). Alcian blue and safranin staining was done on
formalin-fixed paraffin sections. Dewaxing and hydrating of the specimens were
done as described for toluidine staining. Slides were incubated for 15 min in
alcian blue and safranin staining solution (3.6 g/liter alcian blue, 180 mg/liter
safranin, 4.8 g/liter ferric ammonium sulfate in 1 M sodium acetate adjusted to
pH 1.42 with HCl) and washed with water. After dehydration in tert-butanol and
incubation in xylol, slides were mounted in Entellan. Antiheparin antibody stain-
ing was done on acetone-fixed 5-m cryosections. After the sections were
blocked with 0.1 mg/ml mouse IgG in phosphate-buffered saline (PBS) contain-
ing 1% bovine serum albumin, sections were incubated with ST-1 (antiheparin;
IgM) (44) and then with FITC-labeled anti-IgM and allophycocyanin-labeled
anti-c-Kit antibodies. Mast cells in ear skin were counted as metachromatically
(toluidine) stained cells per 10 view fields (5.2 mm) beginning from the tip of the
ear. c-Kit PMC were enumerated as c-Kit peritoneal exudate cells (PEC) by
flow cytometry using counting beads (Caltag).
Western blots. Total PEC were lysed in sample buffer under reducing condi-
tions, and aliquots representing 4  105 PMC were subjected to 11.5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. After transfer onto polyvi-
nylidene difluoride membranes, the blots were probed with antiprotease sera
followed by isotype-specific horseradish peroxidase-conjugated secondary anti-
bodies. Membranes were developed with the ECL system (Pierce). Staining for
c-Kit served as a mast cell-specific positive control. Antisera against Mc-cpa,
Mcp-5, and Mcp-6 were made against mouse proteins (glutathione S-transferase
fusions) in rats. The antiserum against Mcp-4 was made in rabbits against a
surface-exposed peptide coupled to keyhole limpet hemocyanin (10).
Enzyme assays. A total of 5  106 PEC were lysed in 470 l PBS, 2 M NaCl,
0.5% Triton X-100. Seventy microliters of these lysates and 30 l water were
mixed with 20 l substrate (1.8 mM), and the absorbance at 405 nm was mon-
itored. The substrates (Bachem) were Suc-Ala-Ala-Pro-Arg-p-nitroanilide and
N-(4-methoxyphenylazoformyl)-Phe-OH for trypsin-like and Mc-cpa activities,
respectively (15).
Assays for mast cell functions. PMC were treated with 2 M ionomycin in
Tyrode’s buffer (10 mM HEPES, pH 7.4, 130 mM NaCl, 5 mM KCl, 1.4 mM
CaCl2, 1 mM MgCl2, 5.6 mM glucose, 0.1% bovine serum albumin) for 10 min
at 37°C. The degree of degranulation was determined by measuring -hex-
osaminidase release (27). Aliquots of supernatants and pellets from untreated
and ionomycin-treated cells were extracted by three freeze-thaw cycles and
incubated with the substrate p-nitrophenyl-N-acetyl--D-glucosamine (1 mM p-
NAG [Sigma] in 0.1 M sodium citrate, pH 4.5). After 2 h, the reaction was
stopped by the addition of 1 M Tris. Substrate conversion was measured by
absorbance at 405 nm. The degree of degranulation was calculated as the per-
centage of the optical density of the supernatant divided by the optical density of
the supernatant plus pellet. Total histamine content and histamine release after
ionomycin treatment were determined for purified mast cells using an histamine
enzyme immunoassay kit (Beckman Coulter). For passive cutaneous anaphylaxis
(PCA), ears were injected intradermally with 20 ng of murine monoclonal anti-
dinitrophenyl (anti-DNP) IgE (SPE-7) in 15 l PBS or with PBS only. Eighteen
hours later, mice were injected intravenously with 100 g DNP-human serum
albumin (HSA) in 1% Evan’s blue in PBS (all reagents from Sigma). Ear
photographs were taken 5 min after this antigenic challenge.
Analysis of proteoglycan synthesis and detergent lysis. For proteoglycan anal-
ysis, 1.5  105 sorted PMC or 2  106 cultured BMMC were metabolically
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labeled for 18 h with 3.7 MBq/ml [35S]sulfate in sulfate-free Eagle’s minimum
essential medium supplemented with 10% fetal calf serum that had been dia-
lyzed against PBS. Labeled cells were washed twice with PBS and then succes-
sively treated with 50 mM Tris-HCl (pH 7.5) containing 1% (wt/vol) Triton
X-100 (fraction L1) and with 50 mM Tris-HCl (pH 7.5) containing 1% (wt/vol)
Triton X-100 and 2 M KCl (fraction L2). Culture medium and cell extracts L1
and L2 (the latter after 20-fold dilution with 50 mM Tris-HCl, pH 7.0) were
separately applied to DEAE Sepharose FastFlow columns (Amersham Pharma-
cia) equilibrated with 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl and
0.1% Triton X-100. Columns were washed with 10 volumes of equilibration
buffer and subsequently with 10 volumes of 50 mM sodium acetate (pH 4.0)
containing 150 mM NaCl and 0.1% Triton X-100, and total proteoglycans were
eluted with 10 volumes of 50 mM sodium acetate (pH 4.0) containing 2 M NaCl.
Radioactivity was determined by liquid scintillation counting of aliquots of the
eluate fractions. Radioactivity-containing fractions were pooled, diluted, and
applied to a 1-ml HiTrap DEAE Sepharose FastFlow column (Amersham Phar-
macia) equilibrated with 50 mM sodium acetate (pH 4.0) containing 50 mM LiCl.
After the column was washed with 5 ml of this buffer, a 25-ml linear gradient with
a final concentration of 2.5 M LiCl was applied to sequentially elute distinct
glucosaminoglycan classes. Radioactivity in the eluate fractions was determined
by liquid scintillation counting. To degrade N-sulfated glycosaminoglycans (hep-
arin and heparan sulfate), samples were subjected to HNO2 treatment at pH 1.5
as described previously (37) prior to analysis by anion-exchange chromatography.
Electron microscopy. Ear and back skin, tongue, stomach, PEC, and sorted
PMC were prepared for electron microscopy using previously reported protocols
(3, 34). A total of 30 specimens from Mc-cpa/ and Mc-cpa/ and Mc-cpa/
mice were studied by electron microscopy, and all mast cells in these samples
were photographed.
RESULTS
The loss of Mc-cpa protein and carboxypeptidase enzyme
activity in Mc-cpa/ mast cells. A mutant Mc-cpa allele was
generated by homologous recombination in E14 ES cells. The
targeting vector (Fig. 1A) was constructed with the aims (i) to
disrupt the Mc-cpa gene and (ii) to introduce the enhanced
green fluorescent protein gene (Egfp) at the ATG start codon
of the Mc-cpa locus (32, 51) to visualize Mc-cpa-expressing
cells. Three ES cell clones showed homologous recombination
at the Mc-cpa locus by Southern blotting (Fig. 1B). The lox-P-
flanked neo gene was removed from the recombinant Mc-cpa
locus in vitro. Mutant ES cells were injected into blastocysts,
and the resulting chimeras transmitted the mutant allele
through the germ line (Fig. 1C). The Egfp insertion led to a
Mc-cpa-null allele (see below) which we refer to as Mc-cpa.
Consistent with the mast cell lineage-restricted expression of
Mc-cpa (5, 30, 31, 34), Mc-cpa/ mice appeared normal and
healthy, and they were born at the expected Mendelian ratio.
To determine whether the introduced Mc-cpa mutation lead
to a null allele, lysates from PEC (Fig. 1D to F) and BMMC
(not shown) of Mc-cpa/, Mc-cpa/, and Mc-cpa/ mice
were tested for protease expression by Western blotting (Fig.
1D) and for enzyme activity (Fig. 1E and F). The immature
Mc-cpa precursor (50 kDa) (not shown) and the mature form
of Mc-cpa (36 kDa) were expressed in Mc-cpa/ and Mc-
cpa/ mast cells. Consistent with homozygous null alleles,
Mc-cpa/ mast cells lacked Mc-cpa protein expression (Fig.
1D). Interestingly, the expression of other secretory granule
proteases was concomitantly affected. Mc-cpa/ mast cells
also lacked Mcp-5 protein (Fig. 1D) but not mRNA (not
shown) expression. Mcp-4 expression was upregulated, and
Mcp-6 expression was unchanged.
Next, we analyzed whether Mc-cpa is the only enzyme with
carboxypeptidase specificity expressed in mast cells. Lysates
from Mc-cpa/, Mc-cpa/, and Mc-cpa/ peritoneal cells
were incubated with test substrates. Mc-cpa/ and Mc-cpa/
cell lysates cleaved a peptide substrate specific for Mc-cpa
enzyme activity (15). In contrast, Mc-cpa/ mast cells lacked
this enzyme activity entirely (Fig. 1E). As a positive control,
the same lysates were analyzed for cleavage of a substrate
indicative of trypsin-like enzyme activity. The latter activity was
present in cells from all three genotypes (Fig. 1F).
Collectively, introduction of Egfp into the Mc-cpa locus gen-
erated a null allele as shown by the absence of Mc-cpa protein
and its corresponding enzyme activity. To test for Egfp expres-
sion, we developed ES cell-derived mast cells (46, 49) from
targeted ES cells in vitro. Fifteen to 20% of Mc-cpa/ ES
cell-derived mast cells expressed the Egfp gene (not shown).
However, when the Mc-cpa allele was transmitted via the
germ line to Mc-cpa/ or Mc-cpa/ mice, ex vivo-isolated
mast cells did not express Egfp, a fact which has precluded the
use of this mouse line to track Mc-cpa-expressing cells. Pre-
liminary experiments indicate that expression of Egfp from this
locus is prevented by DNA methylation. The molecular basis
for this unexpected marker gene inactivation requires further
investigation.
Phenotype, granule content, and ultrastructure of Mc-
cpa/ mast cells. Mc-cpa expression occurs very early in mast
cell ontogeny (5, 14, 34). Its expression is upregulated in
CTMC which are located mostly in the skin and the peritoneal
cavity. Mc-cpa expression is low in mucosal mast cells (36).
Therefore, we focused our analyses on CTMC. Peritoneal mast
cells, defined by their c-Kit FcεRI phenotype, were present
in both Mc-cpa/ (Fig. 2A) and Mc-cpa/ (Fig. 2B) mice.
Peritoneal mast cell numbers were counted by flow cytometry.
Both the relative percentages of mast cells among PEC and the
absolute mast cell numbers were comparable for Mc-cpa/
mice (1.7%  0.2% [mean  standard deviation] of mast cells
per total PEC; 5.1  104  1.0  104 mast cells per peritoneal
cavity; n 	 8) and Mc-cpa/ mice (1.3%  0.3%; 5.0  104 
1.1  104; n 	 8) mice (Table 1). Sorted peritoneal mast cells
from Mc-cpa/ and Mc-cpa/ mice had the typical granular
appearance following acridine orange staining, a dye specific
for acidic granules (Fig. 2C and D). The numbers of ear skin
mast cells, enumerated histologically by toluidine blue staining,
were also similar in wild-type mice (156  26 cells per 10
microscopic view fields, which corresponds to 5.2 mm; n 	 4),
and Mc-cpa/ mice (140  20 cells; n 	 4) (Table 1). Hence,
the loss of Mc-cpa has no impact on the size of peritoneal and
skin mast cell compartments.
Next, mast cells were examined for their ultrastructure by
transmission electron microscopy (4) (Fig. 2E and F). We
compared by electron microscopy a total of 2,500 mast cells
from Mc-cpa/ (905 mast cells), Mc-cpa/ (709 mast cells),
and Mc-cpa/ (886 mast cells) mice. The age of the mice
analyzed ranged from 45 to 205 days. Cells from all genotypes
contained large numbers of electron-dense mast cell granules.
No morphological differences could be detected in mast cells in
situ in the tongue, in ear and back skin, in the stomach, and
among PEC (not shown) and in peritoneal mast cells sorted
from Mc-cpa/ (Fig. 2E) and Mc-cpa/ (Fig. 2F) mice. Thus,
unlike the loss of Ndst-2 (10, 17), lack of Mc-cpa is not asso-
ciated with a morphologically apparent phenotype.
Peritoneal mast cells of Mc-cpa/mice are histochemically
immature. Mature mast cells can be recognized by metachro-
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matic staining in toluidine blue. Both Mc-cpa/ and Mc-
cpa/ peritoneal and skin mast cells were toluidine blue.
However, there were clear differences in the intensity of tolu-
idine blue staining. In Mc-cpa/ mice, 98% of all peritoneal
mast cells stained very strongly with toluidine blue (Table 1;
Fig. 3H). In contrast, we observed a heterogeneous staining
pattern for Mc-cpa/ mice in which only 26% of peritoneal
mast cells strongly stained with toluidine blue, the remaining
mast cells exhibited low level of staining with toluidine blue
(Fig. 3I and J). In the skin, comparable numbers of mast cells
were recognized by toluidine blue staining in both genotypes
(Table 1), however, the toluidine blue staining was weaker
overall in Mc-cpa/ mice.
Connective tissue and mucosal tissue mast cells can be dis-
tinguished histochemically by their staining pattern using al-
cian blue and safranin. CTMC are AB S, while MMC are
FIG. 1. Generation of Mc-cpa/ mice and protein and enzyme analyses of Mc-cpa/ mast cells. (A) The targeting construct included a short
5 arm, the enhanced green fluorescent protein gene (gfp), the neomycin resistance gene (neo), a long 3 arm including exons 1 (from nucleotide
18 on), 2 and 3, and the thymidine kinase (TK) gene. (B) Southern blot of Mc-cpa/ (/) and Mc-cpa/ (/) ES cell DNA digested with
EcoRV or SphI/XhoI. The 5 probe and expected fragment lengths are shown in panel A. (C) Mc-cpa/, Mc-cpa/, and Mc-cpa/ mice were
identified by single 2.2-kb PCR bands, 2.2-kb and 3.7-kb PCR bands, or single 3.7-kb PCR bands. Lane M contains molecular size markers. wt,
wild type. (D) Western blot analysis of Mc-cpa/, Mc-cpa/, and Mc-cpa/ mast cells shows the absence of Mc-cpa and Mcp-5 proteins in
Mc-cpa/ mast cells. Mcp-4 is upregulated, and Mcp-6 is unaltered. (E and F) Lysates of Mc-cpa/ (■), Mc-cpa/ (E), and Mc-cpa/ (‚)
peritoneal mast cells or the blank control () were analyzed for carboxypeptidase activity (E) and trypsin-like activity (F) by test substrates (15).
Mc-cpa/ mast cells lacked Mc-cpa activity (E). Cells from all genotypes had trypsin-like activity (F). OD405nm, optical density at 405 nm.
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AB S (45). Wild-type and mutant mast cells stained very
differently with these dyes. As expected, Mc-cpa/ peritoneal
mast cells had the fully mature connective tissue phenotype
(AB S) (Table 1; Fig. 3L). In contrast, Mc-cpa/ peritoneal
mast cells included many AB S/low (did not stain with sa-
franin or stained weakly) cells (Table 1; Fig. 3M and N). In
addition to the partial reversal of the alcian blue and safranin
staining, the intracellular pattern of safranin staining was al-
tered in Mc-cpa/ mast cells. Rather than marking discrete
dense granules, as found in wild-type mast cells (Fig. 3L),
safranin appeared to stain larger vacuoles in Mc-cpa/ mast
cells (Fig. 3M and N). In doubly stained cells, blue and brown
areas were compartmentalized (Fig. 3N). For comparison, we
stained in parallel BMMC which showed the typical immature
phenotype (AB S) (Fig. 3O) (11, 26). Hence, Mc-cpa/
peritoneal mast cells are histochemically more immature than
their wild-type counterpart.
FIG. 2. Mc-cpa/ mast cells are normal with regard to staining for
c-Kit and FcεRI expression, acridine orange staining, and transmission
electron microscopy. Peritoneal mast cells from Mc-cpa/ (/) (A,
C, and E) and Mc-cpa/ (/) (B, D, and F) mice were analyzed by
flow cytometry for c-Kit and FcεRI expression (A and B) (for relative
and absolute mast cell frequencies, see Table 1), by acridine orange
staining showing acidic granules (C and D), and by electron micros-
copy to reveal their ultrastructure (E and F). The scale bars in panel D
(12 m) and panel F (8.5 m) apply to panels C and D and panels E
and F, respectively.
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FIG. 3. Mc-cpa/ peritoneal mast cells resemble immature BMMC and possess a mast cell progenitor phenotype. Forward (FSC) and side
scatter (SSC) were determined by flow cytometry for Mc-cpa/ (/) (A, C, and E) and Mc-cpa/ (/) (B, D, F, and G) peritoneal mast cells
(A, B, E, F, and G) and immature BMMC (C and D). Peritoneal mast cells from Mc-cpa/ mice were separated by cell sorting into small (F) and
large (G) subpopulations. Cytospins from the indicated peritoneal mast cell populations were stained with toluidine blue (H to J) and with alcian
blue and safranin (L to N) and compared to BMMC (K and O). The scale bar in panel H (20 m) applies to panels H to O. wt, /; ko, /.
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Mc-cpa/ peritoneal mast cells are immature by flow cyto-
metric scatter. Forward side scatter analysis showed marked
differences between Mc-cpa/ (Fig. 3A) and Mc-cpa/ (Fig.
3B) mast cells when each population was gated as c-Kit peri-
toneal cells. Mc-cpa/ mast cells had a low forward scatter,
indicating relatively small size, and a high side scatter, indicat-
ing high granule content, or normal granule composition (Fig.
3A). By contrast, Mc-cpa/ mast cells had a lower side scatter
and higher forward scatter, suggesting abnormal granule con-
tent or composition and larger size. Parallel analysis of Mc-
cpa/ BMMC (Fig. 3C) and Mc-cpa/ BMMC (Fig. 3D), a
common model of immature mast cells, demonstrated that
BMMC, regardless of their genotype, had a forward side scat-
ter comparable to that of peritoneal mast cells from Mc-cpa/
mice.
This comparison suggested that peritoneal mast cells de-
velop in the following order: (i) high forward scatter-low side
scatter (population 1; Fig. 3G), (ii) low forward scatter-low
side scatter (population 2; Fig. 3F), and (iii) low forward scat-
ter-high side scatter (population 3; Fig. 3E). This idea could be
tested more directly in Mc-cpa/ mice in which populations 1
and 2 were very abundant (Fig. 3B). Mc-cpa/ peritoneal
mast cells were separated into populations 1 (Fig. 3G) and 2
(Fig. 3F), and each population was stained with toluidine and
alcian blue plus safranin. Interestingly, population 1 was in-
deed enriched for cells with a very immature phenotype (AB
S/low) (Fig. 3N). Population 2 cells were mostly ABlow
(stained weakly with alcian blue) S (Fig. 3M), which corre-
sponds to a more mature CTMC phenotype. Fully mature
ABlow Shigh cells were present only in wild-type mice (Fig. 3L).
Thus, Mc-cpa/ peritoneal mast cells include distinct popu-
lations of histochemically immature mast cells.
Age dependency of the immatureMc-cpa/ peritoneal mast
cell phenotype. The presence of AB S/low peritoneal mast
cells in Mc-cpa/ mice showed that the loss of Mc-cpa is
associated with a block in the development of phenotypically
normal connective tissue mast cells in vivo. Because hemato-
poietic processes often change over time (35, 47), we deter-
mined whether this block was age dependent. The kinetics of
the alcian blue and safranin staining phenotype in the perito-
neal cavity in wild-type and Mc-cpa/ mice are shown in Fig.
4. Photomicrographs of PEC cytospins are shown for postnatal
days 12, 57, and 150 (Fig. 4A to F), and all time points of
analysis are summarized in Fig. 4G to J. In healthy mice, the
safranin staining intensity increased with age, but all cells were
AB S regardless of their age (Fig. 4A to C). In contrast, in
very young Mc-cpa/ mice, all peritoneal mast cells were AB
S/low (Fig. 4D). The proportion of AB S/low cells declined
at the expense of AB S with increasing age (Fig. 4D to F).
However, even at 150 days of age, Mc-cpa/ mast cells lacked
the normal staining pattern (Fig. 4F). Collectively, the alcian
blue and safranin staining phenotype of peritoneal mast cells in
Mc-cpa/ mice is changing over time in vivo. The “direction”
of this change points from immature to more mature mast cells
(1).
Probing mast cells for heparin expression by berberine sul-
fate and antiheparin antibody. CTMC contain heparin, while
MMC lack heparin (1). Heparin can be specifically stained in
secretory granules with berberine sulfate which binds with high
affinity to heparin, resulting in strong fluorescence (8). Mast
cells from Mc-cpa/ and Mc-cpa/ mice were visualized
among PEC by acridine orange staining (Fig. 5A and B). Wild-
type mast cells showed the typical berberine staining charac-
terized by intensely fluorescent granules and weakly stained
nuclei (Fig. 5C and F). Interestingly, Mc-cpa/ mast cells
were berberine (Fig. 5D and G) compared to wild-type cells
(Fig. 5C and F). A faint nuclear and perinuclear berberine
staining of Mc-cpa/ mast cells was detectable only after at
least 10-fold-longer exposure of the film to the fluorescence
(Fig. 5G, insert).
Because the absence of berberine fluorescence suggested
that Mc-cpa/ mast cells are devoid of heparin, we next ap-
plied a berberine-independent, heparin-specific reagent to
probe mutant mast cells for the presence of heparin. To this
end, we used a monoclonal antiheparin antibody which can
recognize heparin-expressing cells in frozen skin sections (44).
Skin mast cells were identified by staining for c-Kit (Fig. 5H
and I). c-Kit mast cells always double labeled for antiheparin
antibodies (Fig. 5J and K; overlay in Fig. 5L and M). In con-
trast to the berberine staining of PMC, the overall intensity of
antiheparin staining was comparable in Mc-cpa/ and Mc-
FIG. 4. Age-dependent block in mast cell development in Mc-
cpa/ mice. Peritoneal cells were isolated from wild-type (Mc-cpa/
[/]) (A to C) and Mc-cpa/ (/) (D to F) mice at the indicated
age. Cells were cytospun and stained by alcian blue and safranin.
Relative proportions of AB S (blue) (G), AB S (blue 

brown) (H), AB S (brown 
 blue) (I), and AB S (brown)
(J) staining (, strong staining; , staining; , no staining) are
shown as a function of time.
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cpa/ tissue mast cells. c-Kit was predominantly found at the
cell surface (Fig. 5H and I), whereas heparin was mostly intra-
cellular (Fig. 5L and M). Of note, the antiheparin staining
pattern differed in wild-type and mutant mice. The antiheparin
staining was ring shaped in Mc-cpa/ cells (Fig. 5J and L),
whereas heparin was localized in compact dots in Mc-cpa/
mast cells. Collectively, heparin can be detected by antiheparin
antibody but not by berberine in mutant mast cells. The altered
antibody staining pattern suggests that heparin storage or com-
plex formation is altered in Mc-cpa/ mast cells.
Heparin synthesis and secretion are independent from Mc-
cpa expression. To analyze proteoglycan biosynthesis biochem-
ically, cell sorter purified PMC were metabolically labeled with
[35S]sulfate (10, 15). Labeled cells were first lysed (0.5% Triton
X-100) (soluble fraction termed L1), and subsequently the
insoluble material was extracted under high-salt (2 M KCl)
conditions (soluble fraction termed L2) (Fig. 6A). From Mc-
cpa/ mast cells, most 35S-labeled proteoglycans were recov-
ered in fraction L2 (Fig. 6Aa). In contrast, most 35S-labeled
proteoglycan material was already released from Mc-cpa/
mast cells by the lysis step (L1) (Fig. 6Aa). From immature
BMMC, regardless of their Mc-cpa genotype, proteoglycans
were extracted within L1 (Fig. 6Ab). Thus, proteoglycan ex-
traction is detergent resistant in fully mature peritoneal mast
cells, but it is detergent sensitive in both immature BMMC and
peritoneal Mc-cpa/ mast cells.
The vast majority of proteoglycans from Mc-cpa/ and
Mc-cpa/ mast cells were present in L1 and L2 fractions,
respectively. These fractions were analyzed by ion-exchange
chromatography and LiCl gradient elution to classify the pro-
teoglycan types (Fig. 6Ac). Two distinct peaks emerged: one
eluting at low salt concentration (Fig. 6Ac, left peaks) consis-
tent with chondroitin sulfate, and another one eluting at high
salt concentration consistent with heparin (Fig. 6Ac, right
peaks) (10). For both Mc-cpa/ and Mc-cpa/ mast cells,
heparin peaks were identified by complete degradation with
HNO2 (Fig. 6Ad). On the basis of this biochemical analysis,
heparin synthesis is unaffected by the absence of Mc-cpa.
To analyze proteoglycan secretion, mast cells were pulse-
labeled with [35S]sulfate and then chased, and spontaneous
release (Fig. 6Ae) versus ionomycin-stimulated release (Fig.
6Af) were measured. Both Mc-cpa/ and Mc-cpa/ mast
cells retained their labeled proteoglycans in the cell, and again
proteoglycan extraction required different conditions (L1 ver-
sus L2) (Fig. 6Ae). After ionomycin stimulation, both wild-type
and mutant mast cells released the labeled proteoglycans into
the supernatant; however, release was more complete in Mc-
cpa/ cells than in Mc-cpa/ mast cells (Fig. 6Af). These
experiments demonstrate that, in the absence of Mc-cpa, the
FIG. 5. Berberine fluorescence and immunofluorescence analysis
for heparin expression in Mc-cpa/ mast cells. Peritoneal cells from
wild-type (Mc-cpa/ [/]) (A, C, and F), and Mc-cpa/ (/) (B,
D, E, and G) mice were stained with acridine orange to visualize mast
cells (A and B) and with berberine sulfate to visualize heparin-con-
taining mast cell granules (C to G). Mc-cpa/ peritoneal mast cells
lacked berberine reactivity. Faint nuclear/perinuclear berberine fluo-
rescence was detectable after 10-fold-longer exposure of the film to the
fluorescence in Mc-cpa/ mast cells (G). Skin sections from wild-type
(H, J, and L) and Mc-cpa/ (I, K, and M) mice were analyzed by
immunofluorescence analysis using antiheparin and anti-c-Kit antibod-
ies for the presence of cells expressing c-Kit (H and I), and heparin (J
and K). Overlays are shown in panels L and M. All mast cells coex-
pressed c-Kit and heparin. The scale bars in panels E (20 m), F (15
m), and K (10 m) apply to panels A to E, F and G, and H to M,
respectively.
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syntheses of heparin and chondroitin sulfate are normal and
that heparin presumably enters the correct secretory pathway.
The rapid extraction of proteoglycans from Mc-cpa/ mast
cells by detergent only may be due to altered proteoglycan
storage in the cells. However, this was unlikely, given that both
synthesis and regulated secretion of heparin were normal in
the mutant cells. To determine the impact of detergent on
wild-type and mutant mast cells more directly, cells were cy-
tospun in the presence of increasing amounts of Triton X-100
and stained with toluidine blue. When wild-type mast cell were
subjected to this treatment, their metachromatic staining de-
creased and the cells flattened but did not disintegrate (Fig.
6Ba to d). In marked contrast, Mc-cpa/ mast cells showed
“holes” even at low detergent concentrations, and the cells
were entirely lysed at higher concentrations (Fig. 6Be to h).
Thus, Mc-cpa/ and Mc-cpa/ mast cells differ in their de-
tergent resistance. While the underlying molecular basis re-
mains to be uncovered, it is clear that immature BMMC and
Mc-cpa/ but not Mc-cpa/ peritoneal mast cells are highly
detergent sensitive.
Normal functions of Mc-cpa/ mast cells. To determine
whether mast cells lacking Mc-cpa were functionally impaired,
we tested several mast cell functions in vitro and in vivo. First,
the capacity of mutant mast cells for degranulation was mea-
sured by hexosaminidase release after stimulation with iono-
mycin. This stimulus was chosen because PMC, regardless of
their Mc-cpa genotype, were refractory to FcεRI-mediated
stimulation in vitro. The magnitudes of hexosaminidase release
were comparable in Mc-cpa/ and Mc-cpa/ mast cells (Ta-
ble 2). Second, we determined histamine content and release.
Both were similar in Mc-cpa/ and Mc-cpa/ mast cells
(Table 2).
An important in vivo mast cell function, the immediate hy-
persensitivity reaction, was analyzed by local passive cutaneous
anaphylaxis. Ears were injected intradermally with anti-DNP
IgE or, as a negative control, with PBS. On the next day,
DNP-HSA together with Evan’s blue was injected intrave-
nously. Within 5 min after this antigenic challenge, the mast
cell-dependent PCA increased the vascular permeability, caus-
ing local dye extravasation in IgE- but not in PBS-injected skin
(Fig. 7). We analyzed PCA in mice of all three genotypes
(Mc-cpa/ [n 	 5], Mc-cpa/ [n 	 5], and Mc-cpa/ [n 	
5]). The onset and magnitude of dye extravasation were similar
in all genotypes (Fig. 7). Collectively, Mc-cpa/ mast cells
displayed hallmarks of immaturity but showed normal func-
tions in these in vitro and in vivo assays.
DISCUSSION
Mc-cpa and mast cell ontogeny. Developing mast cells di-
verge at an unknown branch into two sublineages, connective
FIG. 6. (A) Heparin biosynthesis and secretion in Mc-cpa/ and
Mc-cpa/ mast cells. Sorted peritoneal (a) or cultured BM-derived
(b) mast cells were metabolically labeled by overnight culture in me-
dium containing [35S]sulfate. Percent radioactivity in counts per
minute (cpm) recovered in either the lysis fraction (L1) or salt extrac-
tion fraction (L2) is shown for Mc-cpa/ (/) (solid bars) and
Mc-cpa/ (/) (open bars) mast cells. Proteoglycans were further
fractionated by ion-exchange chromatography and LiCl gradient elu-
tion (c). The left and right peaks correspond to chondroitin sulfate and
heparin, respectively (10). The heparin peaks disappeared after treat-
ment of the material with HNO2 prior to ion-exchange chromatogra-
phy (d). The left y axes in panels c and d show percent counts per
minute, and the right y axes show conductivity of the LiCl gradient in
milli-Siemens per centimeter. Mast cells were pulse-chase-labeled with
35S. There was no spontaneous release into the supernatant (sup), but
the material was retained in fractions L1 and L2 (e). w/o, without
ionomycin. Following ionomycin (iono) stimulation, mast cells re-
leased labeled proteoglycans into the supernatant (sup) (f). (B) Mc-
cpa/ mast cells are highly detergent sensitive. Peritoneal mast cells
from Mc-cpa/ (a to d) and Mc-cpa/ (e to h) mice were cytocen-
trifuged in the absence (without [w/o]) (a and e) or presence of in-
creasing amounts of Triton X-100(0.016% [b and f], 0.02% [c and g],
and 0.5% [d and h]) and stained with toluidine blue. Wild-type mast
cells withstood this treatment up to 0.5% Triton X-100 (d) but Mc-
cpa/ mast cells showed “holes” at low detergent concentrations (f)
and disintegrated entirely at higher concentrations (g and h). The
arrowheads in panel h point to the remaining nuclei. The scale bar in
panel E (20 m) applies to panels a to h.
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tissue and mucosal mast cells. The onset of Mc-cpa expression
occurs at the mast cell progenitor stage (34), and Mc-cpa
expression increases as immature mast cells mature into
CTMC but not MMC (36). The loss of Mc-cpa changes the
phenotype of CTMC towards an immature mast cell pheno-
type, demonstrating that Mc-cpa expression is not only associ-
ated with CTMC maturation but is required for the generation
of fully mature peritoneal mast cells as defined by classical
histochemistry. This phenotype points to an important intra-
cellular function for Mc-cpa in CTMC development.
Mc-cpa and proteoglycan syntheses. Mc-cpa/ mast cells
and BMMC share several hallmarks of immature mast cells.
The pattern of alcian blue and safranin binding to mast cell
granules distinguishes BMMC and CTMC. On the basis of
their reactivity with these dyes, Mc-cpa/ CTMC appear to be
at an intermediate stage between immature BMMC and ma-
ture Mc-cpa/ CTMC. It has been assumed that the correla-
tion between mast cell maturation and histochemical pheno-
type is indicative of the proteoglycan type which is
predominantly expressed in BMMC (chondroitin sulfate) and
CTMC (heparin) (1, 14, 45). Previous experiments using total
peritoneal exudate cells which include, in addition to mast
cells, lymphocytes and macrophages, had suggested that the
source of chondroitin sulfate among peritoneal exudate cells is
non-mast cells (10). In contrast, we show that proteoglycan
synthesis by highly purified peritoneal masts was not limited to
heparin but also included chondroitin sulfate. Despite the fact
that wild-type and Mc-cpa/ CTMC synthesized chondroitin
sulfate and heparin, they differed in their histochemical phe-
notype. Thus, alcian blue and safranin staining does not faith-
fully reflect whether chondroitin sulfate or heparin are synthe-
sized.
Is Mc-cpa involved in heparin sorting? The majority of
Mc-cpa protein forms a high-molecular-weight complex with
proteoglycans inside mast cells (36). This complex formation is
probably due to the fact that Mc-cpa and heparin are highly
positively and negatively charged, respectively. Formation of
Mc-cpa-proteoglycan complexes could occur as soon as both
come into proximity, e.g., in the Golgi apparatus where the
complex is sorted into the secretory granules (39). Car-
boxypeptidase E is an example of a carboxypeptidase which
functions as a sorting receptor for secretory pathway proteins,
including prohormones, in neuroendocrine pituitary cells (2).
The close association of Mc-cpa and heparin raised the possi-
bility that sorting of heparin into the secretory pathway is a
Mc-cpa-dependent process. However, we have shown that Mc-
cpa/ CTMC can secrete heparin in a regulated manner,
ruling out an obligatory requirement for Mc-cpa (or Mcp-5)
expression for heparin sorting.
Interdependence of Mc-cpa and Mcp-5 expression. Ndst-2-
deficient mast cells lack sulfated heparin and fail to express
Mcp-4, Mcp-5, Mcp-6, and mature Mc-cpa protein (10, 15, 17).
Thus, heparin synthesis is essential for protease protein expres-
sion or stability. Mc-cpa and Mcp-5 are highly dependent on
each other, because Mcp-5-null mice lack Mc-cpa protein (43)
and Mc-cpa-null mice lack Mcp-5 protein (this paper). The
absence of Mcp-5 protein in Mc-cpa/ mast cells is not due to
the absence of transcription, because Mcp-5 mRNA was ex-
pressed normally (not shown). In contrast to Ndst-2-deficient
mast cells, Mcp-6 expression was unaffected and Mcp-4 expres-
sion was even upregulated in Mc-cpa/ mast cells (Fig. 1).
While the molecular mechanism underlying these strong alter-
ations remains to be found, it is clear that mast cell proteases
depend not only on heparin but also upon each other in order
to be expressed in their physiological stoichiometry. In the case
of Mc-cpa and Mcp-5, it is likely that these two proteins form
a direct complex.
Proteoglycans and mast cell morphology. Histochemical pa-
rameters have been widely used to assess mast cell maturation.
In vivo, PMC change their phenotype from AB S (imma-
ture) in 1-week-old rats to AB S (mature) in 3-week-old rats
(1). In mast cell cultures, high doses of Kit ligand can induce a
FIG. 7. Mc-cpa/ mast cells mount a normal passive cutaneous
anaphylaxis reaction. Mc-cpa/, Mc-cpa/, and Mc-cpa/ mice
were injected intradermally into the left and right ears with hapten
(DNP)-specific IgE or PBS, respectively. On the next day, mice were
challenged by intravenous injection of hapten-carrier (DNP-HSA) to-
gether with Evan’s blue. The PCA reaction is evident by extravasation
of the dye in IgE-injected but not in control PBS-injected ears. Mice of
all genotypes mounted indistinguishable PCA reactions. One repre-
sentative mouse of five mice for each genotype are shown.
TABLE 2. Hexosaminidase and histamine release from wild-type and mutant mast cellsa
Genotypeb
% -Hexosaminidase release (n)c
Histamine
Total amt (nmol/cell) (n)d
% Release (n)c
w/o Ionomycin w/o Ionomycin
/ 4.6  2.4 (3) 80.0  5.1 (3) 123.7  3.1 (3) 3.3 92.6
/ 5.7  1.0 (3) 82.1  10.6 (3) 115.0  22.6 (3) 4.3 95.2
a Cell sorter-purified mast cells from Mc-cpa/ and Mc-cpa/ mice were left untreated or stimulated with ionomycin. Hexosaminidase and histamine were
measured by colorimetric assay and by enzyme-linked immunosorbent assay, respectively.
b /, Mc-cpa/; /, Mc-cpa/.
c Release into the supernatant with or without ionomycin stimulation (w/o). Percentages of the release of hexosaminidase and histamine were calculated relative to
the total hexosaminidase and histamine contents. n, number of mice.
d The total amount of histamine was determined by comparison to a histamine standard curve. n, number of mice.
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histochemical shift from AB S towards AB S cells (14,
45). Comparison of mice lacking Ndst-2 (10, 17), Mcp-5 (43), or
Mc-cpa (this paper) shows that Ndst-2, but not Mcp-5 or Mc-
cpa, is required for the generation of morphologically normal
mast cell granules. With regard to the Mc-cpa/ mice, it is
surprising that mutant mast cells showed aberrantly strong
alcian blue and weak safranin staining (Fig. 3 and 4) yet normal
ultrastructural mast cell morphology (Fig. 2). Aliquots of the
mast cells sorted for subsequent electron microscopy analysis
were analyzed by alcian blue and safranin staining and showed
the phenotypic distribution shown in Table 1. We have exam-
ined the ultrastructure of a large number of mast cells by
electron microscopy (2,500 cells), and there was no greater
morphological heterogeneity in Mc-cpa/ mast cells than in
Mc-cpa/ mast cells. In this case, a prominent histochemical
mast cell phenotype does not translate into ultrastructural al-
terations.
Mc-cpa and detergent sensitivity. One striking aspect of the
Mc-cpa/ mast cell phenotype is the differential detergent
sensitivity comparing wild-type (resistant), Mc-cpa/ (sensi-
tive) peritoneal mast cells and BMMC (sensitive). We noticed
this difference initially by the fact that Mc-cpa/ but not
Mc-cpa/ PMC released labeled macromolecular material
following detergent lysis (Fig. 6). Pulse-chase experiments
strongly suggest that proteoglycan synthesis and routing into
the regulated secretory pathway occur independently from Mc-
cpa expression. However, the integrity of the mutant mast cells
appears to be affected dramatically as shown by detergent
titration (Fig. 6). Cell membranes are composed of detergent-
resistant and detergent-sensitive material (38). How the ab-
sence of Mc-cpa causes the detergent-sensitive phenotype re-
mains to be determined.
Age-dependent phenotype of Mc-cpa/ peritoneal mast
cells. With increasing age, Mc-cpa/ PMC acquired a more
mature, but never a completely normal histochemical pheno-
type (Fig. 4). The peritoneal cavity is colonized by mast cells
early in life (1), and there is very little turnover of peritoneal
mast cells in the absence of inflammation. In fact, six weeks
following BM-transplantation into lethally irradiated mice,
only 2% of PMC were replaced by donor stem cell-derived
mast cells (C. Waskow and H.-R. Rodewald, unpublished).
Therefore, it is likely that the phenotypically distinct mast cells
from young and old Mc-cpa/ mice are precursor and product
within the peritoneal cavity.
Role of Mc-cpa in mast cell function. We have uncovered an
intracellular requirement for Mc-cpa in mast cell maturation.
Despite this immature phenotype, Mc-cpa/ mast cells were
normal with regard to mediator degranulation in vitro and
PCA in vivo. These data imply that Mc-cpa is not required for
immediate mast cell responses. However, Mc-cpa may be in-
volved in delayed allergic responses and in mast cell-mediated
inflammation. Physiological substrates of Mc-cpa are presently
unknown. Several functions for Mc-cpa have been proposed.
For instance, Mc-cpa can process angiotensin in combination
with Mcp-4 in vitro (20). Pancreatic carboxypeptidase A cata-
lyzes leukotriene conversion (29) which may also occur via
Mc-cpa in mast cells. A role for Mc-cpa in endothelin-1 deg-
radation has been suggested in one report (24) but not in
another report (23). It remains to be determined whether
Mc-cpa plays a role in these pathways in vivo. Experiments
addressing these questions using Mc-cpa/ mice are under
way.
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